Gastroenterologycetuximabliquid biopsy
Precision Rechallenge: Liquid Biopsy CGP Refines Patient Selection in Metastatic Colorectal Cancer
By MedXY|Jan 8, 2026
The randomized CAVE-2 GOIM trial demonstrates that while adding avelumab to cetuximab rechallenge does not improve survival in metastatic colorectal cancer, liquid biopsy-based genomic hyper-selection identifies a subgroup of patients with
